Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $59,484.80 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin B. Klee sold 18,589 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $59,484.80. Following the transaction, the chief executive officer now directly owns 3,120,569 shares of the company’s stock, valued at approximately $9,985,820.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $3.12 on Friday. The firm has a market cap of $212.18 million, a PE ratio of -2.92 and a beta of -0.55. The firm’s 50 day simple moving average is $2.42 and its 200-day simple moving average is $2.16. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to the consensus estimate of $18.83 million. During the same period last year, the firm earned $0.31 earnings per share. Equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Analyst Ratings Changes

AMLX has been the subject of several recent analyst reports. The Goldman Sachs Group boosted their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.60.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC increased its position in Amylyx Pharmaceuticals by 52,575.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after purchasing an additional 15,247 shares during the period. Algert Global LLC bought a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $47,000. CWM LLC increased its holdings in Amylyx Pharmaceuticals by 104.2% during the second quarter. CWM LLC now owns 28,643 shares of the company’s stock valued at $54,000 after buying an additional 14,613 shares during the period. SG Americas Securities LLC raised its stake in Amylyx Pharmaceuticals by 113.6% in the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after buying an additional 29,697 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in Amylyx Pharmaceuticals by 57.9% during the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after buying an additional 27,954 shares during the period. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.